Quick Answer
ALNYLAM PHARMACEUTICALS, INC. reported Cash and Equivalents of $1.66 billion for fiscal year 2025.
ALNYLAM PHARMACEUTICALS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $1.66B | +71.5% |
| 2024 | $966.43M | +18.9% |
| 2023 | $812.69M | -6.2% |
| 2022 | $866.39M | +5.7% |
| 2021 | $819.98M | +65.1% |
| 2020 | $496.58M | -9.2% |
| 2019 | $547.18M | +30.2% |
| 2018 | $420.15M | -34.9% |
| 2017 | $645.36M | +233.3% |
| 2016 | $193.62M | +7.0% |
| 2015 | $180.90M | +140.6% |
| 2014 | $75.18M | +41.4% |
| 2013 | $53.17M | +3.4% |
| 2012 | $51.41M | -26.8% |
| 2011 | $70.23M | -5.9% |
| 2010 | $74.60M | -45.7% |
| 2009 | $137.47M | -28.3% |
| 2008 | $191.79M | +82.4% |
| 2007 | $105.16M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.49B | +35.5% | +33.8% |
| June 30, 2025 | $1.11B | +15.0% | +9.2% |
| March 31, 2025 | $1.02B | +49.5% | +5.5% |
| December 31, 2024 | $966.43M | +18.9% | -12.1% |
| September 30, 2024 | $1.10B | +6.5% | +13.6% |
| June 30, 2024 | $968.49M | +47.2% | +42.0% |
| March 31, 2024 | $681.88M | +1.4% | -16.1% |
| December 31, 2023 | $812.69M | -6.2% | -21.3% |
- ALNYLAM PHARMACEUTICALS, INC. showed an increase of +71.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2007–2025 period, ALNYLAM PHARMACEUTICALS, INC.’s cash and equivalents has grown by 1476.0% (from $105.16 million to $1.66 billion).
- The most recent figure is from ALNYLAM PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: